Immuneering Appoints Grant Bogle to Board of Directors
- Immuneering appointed Grant Bogle to its board of directors, effective November 9, 2026.
- Bogle most recently served on Nuvalent's board; his prior roles include Epizyme CEO and TESARO chief commercial officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090730PRIMZONEFULLFEED9872407) on November 09, 2026, and is solely responsible for the information contained therein.